A validated UPLC-MS/MS method for quantitative determination of a potent neuroprotective agent Sarsasapogenin-AA13 in rat plasma: Application to pharmacokinetic studies.

A validated UPLC-MS/MS method for quantitative determination of a potent neuroprotective agent Sarsasapogenin-AA13 in rat plasma: Application to pharmacokinetic studies. Biomed Chromatogr. 2019 Dec 17;:e4775 Authors: Pei L, Ye Y, Zhao W, Ye Q, Ge S, Jiang ZW, Liang XQ, Gan HX, Ma L Abstract Sarsasapogenin-AA13(AA13), a sarsasapogenin derivative, exhibited good neuroprotective and anti-inflammatory activities in vitro and therapeutic effects on learning and memory dysfunction in Amyloid-β-injected mice. A sensitive UPLC-MS/MS method was developed and validated to determine AA13 in rat plasma which was further applied to evaluate the pharmacokinetic behaviour of AA13 in rats after taking an intravenous and oral administration of AA13. UPLC-MS/MS was used to determine all the plasma samples. This method was validated to exhibit excellent linearity in the concentration range of 1-1000 ng/mL. The lower limit of quantification was 1 ng/mL for AA13 in rat plasma. Intra-day accuracy for AA13 was 90-114% and inter-day accuracy was 97-103 %.the RSD of intra-day and inter-day assay were less than 15%. After a single oral medication administration of AA13 at the dose of 25 mg/kg, Cmax of AA13 was 1266.4 ± 316.1 ng/mL. AUC0-48 h was 6928.5 ± 1990.1 h·ng/mL, and T1/2 was 10.2 ± 0.8 h. Under intravenous administration of AA13 at a dosage of 250 μg/kg, AUC0-48 h was 785.7 ± 103.3 h⋅ng/mL, and T1/2 was 20.8 ± 7.2 h. Based on the results, or...
Source: Biomedical Chromatography : BMC - Category: Biomedical Science Authors: Tags: Biomed Chromatogr Source Type: research